iCuraDx delivers advanced Multiplex Immunofluorescence (mIF) services designed to give researchers a deeper, more accurate understanding of complex tissue biology. Their team specializes in developing custom mIF panels tailored to each study’s scientific questions, biomarkers of interest, and therapeutic focus. Whether you’re profiling immune cell populations, characterizing the tumor microenvironment, or validating biomarker signatures, iCuraDx provides highly precise, spatially resolved data that drives translational and clinical decision-making.

In addition to fully custom panel development, iCuraDx offers a suite of validated, ready-to-run mIF panels, including the Akoya MOTiF lung panel, which acts as a powerful pan-cancer immune checkpoint panel. This well-established panel includes key markers such as PanCK (AE1/AE3), CD8, CD68, FoxP3, PD-1, and PD-L1, enabling comprehensive profiling across multiple tumor types—NSCLC, breast cancer, prostate cancer, and colorectal carcinoma, among others. These panels allow researchers to quantify immune infiltration, understand checkpoint expression patterns, and evaluate therapeutic response with high sensitivity and spatial precision.

iCuraDx combines high-resolution imaging, optimized staining workflows, and expert data analysis to ensure each mIF study delivers robust, reproducible insights. Their spatial biology expertise allows sponsors to visualize cell-cell interactions, phenotype key immune subsets, and uncover microenvironment dynamics that are not detectable through traditional IHC or single-marker assays.

If your research requires accurate immune profiling, biomarker validation, or tumor microenvironment mapping, iCuraDx’s mIF services offer a powerful, clinical-grade solution that accelerates discovery and enhances the impact of your translational research.